Cargando…

Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers

OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Qahtani, Khalid H., Al-Asiri, Mushabbab, Tunio, Mutahir A., Aljohani, Naji J., Bayoumi, Yasser, Al-Hussain, Hussain, Maklad, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404478/
https://www.ncbi.nlm.nih.gov/pubmed/25828281
http://dx.doi.org/10.15537/smj.2015.4.10341
_version_ 1782367497175957504
author Al-Qahtani, Khalid H.
Al-Asiri, Mushabbab
Tunio, Mutahir A.
Aljohani, Naji J.
Bayoumi, Yasser
Al-Hussain, Hussain
Maklad, Ahmed M.
author_facet Al-Qahtani, Khalid H.
Al-Asiri, Mushabbab
Tunio, Mutahir A.
Aljohani, Naji J.
Bayoumi, Yasser
Al-Hussain, Hussain
Maklad, Ahmed M.
author_sort Al-Qahtani, Khalid H.
collection PubMed
description OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes. RESULTS: The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%). CONCLUSION: The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates.
format Online
Article
Text
id pubmed-4404478
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-44044782015-04-28 Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers Al-Qahtani, Khalid H. Al-Asiri, Mushabbab Tunio, Mutahir A. Aljohani, Naji J. Bayoumi, Yasser Al-Hussain, Hussain Maklad, Ahmed M. Saudi Med J Original Article OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes. RESULTS: The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%). CONCLUSION: The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates. Saudi Medical Journal 2015 /pmc/articles/PMC4404478/ /pubmed/25828281 http://dx.doi.org/10.15537/smj.2015.4.10341 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Al-Qahtani, Khalid H.
Al-Asiri, Mushabbab
Tunio, Mutahir A.
Aljohani, Naji J.
Bayoumi, Yasser
Al-Hussain, Hussain
Maklad, Ahmed M.
Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title_full Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title_fullStr Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title_full_unstemmed Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title_short Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
title_sort prevalence and treatment outcomes of second primary malignancies in saudi patients with differentiated thyroid cancers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404478/
https://www.ncbi.nlm.nih.gov/pubmed/25828281
http://dx.doi.org/10.15537/smj.2015.4.10341
work_keys_str_mv AT alqahtanikhalidh prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT alasirimushabbab prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT tuniomutahira prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT aljohaninajij prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT bayoumiyasser prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT alhussainhussain prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers
AT makladahmedm prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers